Jameela Sheikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jameela Sheikh has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
John Allotey
3 shared publicationsMagnus Yap
College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
3 shared publications- Punith Kempegowda
Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health University of Birmingham Birmingham UK
3 shared publications Shakila Thangaratinam
3 shared publicationsTania Kew
College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
3 shared publicationsAsma Khalil
St George’s University of London, London, UK
2 shared publications
Latest Publications
- 5 November 2026
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
Classification of brain variants on fetal ultrasound: international Delphi consensus
Objective: To develop an expert consensus classification and management framework for fetal‐brain variants identified on prenatal ultrasound across all trimesters of pregnancy that cannot be categorized confidently as either benign or pathological. Methods: A two‐round international Delphi survey was conducted among experts in fetal medicine and neurosonography, with survey data collected between September 2025 and March 2026. Forty‐eight fetal‐brain variants, identified through a scoping literature review of PubMed/MEDLINE from database inception to August 2025, performed between June and August 2025, and illustrated with representative ultrasound images, were evaluated. Brain variants were classified according to clinical significance and recommended management into three predefined categories: ‘green’ (benign variants requiring no additional investigation or follow‐up), ‘orange’ (requiring neurosonographic follow‐up) and ‘red’ (requiring dedicated neurosonography, fetal‐brain magnetic resonance imaging and/or genetic investigations). Consensus was predefined as ≥ 70% agreement. In Round 2, experts confirmed their agreement regarding categorization of variants that had reached consensus in Round 1 and reassessed variants that did not reach initial consensus. Results: Forty‐eight experts from 14 countries participated in Round 1 and 39 (81.3%) completed both rounds. Of the 48 evaluated variants, 35 (72.9%) reached consensus after two rounds: 12 were classified as ‘green’, seven as ‘orange’ and 16 as ‘red’. Green variants included isolated choroid plexus cysts < 10 mm across all trimesters, regular asymmetry of the choroid plexuses, isolated cavum septations, cavum vergae, cavum velum interpositum, isolated small cavum septi pellucidi with intact corpus callosum and dolichocephaly with normal head circumference and normal brain morphology. Orange variants included isolated enlargement of intracranial translucency with preserved anatomy, large or bilateral choroid plexus cysts, isolated enlargement of subarachnoid spaces without compression and isolated cyst of the cavum septi pellucidi. Red variants included abnormal posterior fossa markers (loss of normal three‐space anatomy, increased brainstem–vermis angle, reduced brainstem–occipital bone distance), periventricular cysts associated with adjacent white‐matter abnormalities, thickened corpus callosum and distortion of the interhemispheric fissure, among other findings. Thirteen (27.1%) variants failed to reach consensus, highlighting persistent uncertainty in interpreting subtle isolated asymmetries and selected cystic variants. Conclusions: This international Delphi consensus proposes an initial expert‐derived classification of commonly encountered feta‐brain variants on ultrasound. Because the classification has not been validated against postnatal imaging or neurodevelopmental outcomes and reproducibility has not been assessed, prospective evaluation is required before it can be applied in routine practice. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.
- 5 November 2026
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
Classification of brain variants on fetal ultrasound: international Delphi consensus
Objective: To develop an expert consensus classification and management framework for fetal‐brain variants identified on prenatal ultrasound across all trimesters of pregnancy that cannot be categorized confidently as either benign or pathological. Methods: A two‐round international Delphi survey was conducted among experts in fetal medicine and neurosonography, with survey data collected between September 2025 and March 2026. Forty‐eight fetal‐brain variants, identified through a scoping literature review of PubMed/MEDLINE from database inception to August 2025, performed between June and August 2025, and illustrated with representative ultrasound images, were evaluated. Brain variants were classified according to clinical significance and recommended management into three predefined categories: ‘green’ (benign variants requiring no additional investigation or follow‐up), ‘orange’ (requiring neurosonographic follow‐up) and ‘red’ (requiring dedicated neurosonography, fetal‐brain magnetic resonance imaging and/or genetic investigations). Consensus was predefined as ≥ 70% agreement. In Round 2, experts confirmed their agreement regarding categorization of variants that had reached consensus in Round 1 and reassessed variants that did not reach initial consensus. Results: Forty‐eight experts from 14 countries participated in Round 1 and 39 (81.3%) completed both rounds. Of the 48 evaluated variants, 35 (72.9%) reached consensus after two rounds: 12 were classified as ‘green’, seven as ‘orange’ and 16 as ‘red’. Green variants included isolated choroid plexus cysts < 10 mm across all trimesters, regular asymmetry of the choroid plexuses, isolated cavum septations, cavum vergae, cavum velum interpositum, isolated small cavum septi pellucidi with intact corpus callosum and dolichocephaly with normal head circumference and normal brain morphology. Orange variants included isolated enlargement of intracranial translucency with preserved anatomy, large or bilateral choroid plexus cysts, isolated enlargement of subarachnoid spaces without compression and isolated cyst of the cavum septi pellucidi. Red variants included abnormal posterior fossa markers (loss of normal three‐space anatomy, increased brainstem–vermis angle, reduced brainstem–occipital bone distance), periventricular cysts associated with adjacent white‐matter abnormalities, thickened corpus callosum and distortion of the interhemispheric fissure, among other findings. Thirteen (27.1%) variants failed to reach consensus, highlighting persistent uncertainty in interpreting subtle isolated asymmetries and selected cystic variants. Conclusions: This international Delphi consensus proposes an initial expert‐derived classification of commonly encountered feta‐brain variants on ultrasound. Because the classification has not been validated against postnatal imaging or neurodevelopmental outcomes and reproducibility has not been assessed, prospective evaluation is required before it can be applied in routine practice. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.
- Open Access
- 27 October 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 71
Implementing antenatal vaccination in Europe: policy frameworks, barriers, and approaches for improving uptake
- 27 October 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 71
Open AccessImplementing antenatal vaccination in Europe: policy frameworks, barriers, and approaches for improving uptake
- Open Access
- 21 April 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (4) , e015815
Global maternal mortality associated with SARS-CoV-2 infection: a systematic review and meta-analysis
Background: Pregnant and recently pregnant women infected with SARS-CoV-2 are at increased risk of death and serious complications than those without the infection. The extent of variation in mortality rates in pregnant women with SARS-CoV-2 infection across regions, and the causes of death are not known. We systematically reviewed all available evidence on the variation in mortality rates in pregnant women with SARS-CoV-2 infection across geographical and country income groups, and the reported cause of death. Methods: We searched major databases (December 2019–January 2023) including Medline, LILACS, BIREME and Embase. We included studies that reported deaths in at least 10 consecutive pregnant or recently pregnant women with confirmed SARS-CoV-2 infection and assessed the studies’ risk of bias. We calculated the summary estimates of any cause of death as proportions with 95% CIs using a multilevel random-effects logistic regression model. Subgroup analyses were performed by geographical region and country income groups. We used International Statistical Classification of Diseases and Related Health Problems-Maternal Mortality to categorise the reported cause of death. Findings: From 1 326 315 citations, we included 169 studies (319 172 women with confirmed SARS-CoV-2 infection; 4253 women died). The overall rate of unspecified maternal death was 0.87% (95% CI 0.64% to 1.16%). There were significant differences between geographical regions in rates of maternal mortality, with the highest rates in Sub-Saharan Africa (3.48%; 95% CI 0.66% to 16.42%) and Latin America and the Caribbean (3.16%, 95% CI 1.53% to 6.43%). Rates of maternal mortality varied by country income groups, with the highest rates in low-income countries (4.66%, 95% CI 0.75% to 24.07%). Among women with reported cause of death, 98.6% (2,390/2,423) of deaths were attributable to COVID-19. Interpretation: Rates of deaths in pregnant and recently pregnant women with SARS-CoV-2 infection vary significantly across regions and by country income groups, with the highest burden in Sub-Saharan Africa and low-income countries. COVID-19 is the main reported cause of death. PROSPERO registration number: CRD42020224120.
- 21 April 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (4) , e015815
Open AccessGlobal maternal mortality associated with SARS-CoV-2 infection: a systematic review and meta-analysis
Background: Pregnant and recently pregnant women infected with SARS-CoV-2 are at increased risk of death and serious complications than those without the infection. The extent of variation in mortality rates in pregnant women with SARS-CoV-2 infection across regions, and the causes of death are not known. We systematically reviewed all available evidence on the variation in mortality rates in pregnant women with SARS-CoV-2 infection across geographical and country income groups, and the reported cause of death. Methods: We searched major databases (December 2019–January 2023) including Medline, LILACS, BIREME and Embase. We included studies that reported deaths in at least 10 consecutive pregnant or recently pregnant women with confirmed SARS-CoV-2 infection and assessed the studies’ risk of bias. We calculated the summary estimates of any cause of death as proportions with 95% CIs using a multilevel random-effects logistic regression model. Subgroup analyses were performed by geographical region and country income groups. We used International Statistical Classification of Diseases and Related Health Problems-Maternal Mortality to categorise the reported cause of death. Findings: From 1 326 315 citations, we included 169 studies (319 172 women with confirmed SARS-CoV-2 infection; 4253 women died). The overall rate of unspecified maternal death was 0.87% (95% CI 0.64% to 1.16%). There were significant differences between geographical regions in rates of maternal mortality, with the highest rates in Sub-Saharan Africa (3.48%; 95% CI 0.66% to 16.42%) and Latin America and the Caribbean (3.16%, 95% CI 1.53% to 6.43%). Rates of maternal mortality varied by country income groups, with the highest rates in low-income countries (4.66%, 95% CI 0.75% to 24.07%). Among women with reported cause of death, 98.6% (2,390/2,423) of deaths were attributable to COVID-19. Interpretation: Rates of deaths in pregnant and recently pregnant women with SARS-CoV-2 infection vary significantly across regions and by country income groups, with the highest burden in Sub-Saharan Africa and low-income countries. COVID-19 is the main reported cause of death. PROSPERO registration number: CRD42020224120.
- Top Cited PapersOpen Access
- 4 April 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (4) , e014247
Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis
Objective: To assess the effects of COVID-19 vaccines in women before or during pregnancy on SARS-CoV-2 infection-related, pregnancy, offspring and reactogenicity outcomes. Design: Systematic review and meta-analysis. Data sources: Major databases between December 2019 and January 2023. Study selection: Nine pairs of reviewers contributed to study selection. We included test-negative designs, comparative cohorts and randomised trials on effects of COVID-19 vaccines on infection-related and pregnancy outcomes. Non-comparative cohort studies reporting reactogenicity outcomes were also included. Quality assessment, data extraction and analysis: Two reviewers independently assessed study quality and extracted data. We undertook random-effects meta-analysis and reported findings as HRs, risk ratios (RRs), ORs or rates with 95% CIs. Results: Sixty-seven studies (1 813 947 women) were included. Overall, in test-negative design studies, pregnant women fully vaccinated with any COVID-19 vaccine had 61% reduced odds of SARS-CoV-2 infection during pregnancy (OR 0.39, 95% CI 0.21 to 0.75; 4 studies, 23 927 women; I2=87.2%) and 94% reduced odds of hospital admission (OR 0.06, 95% CI 0.01 to 0.71; 2 studies, 868 women; I2=92%). In adjusted cohort studies, the risk of hypertensive disorders in pregnancy was reduced by 12% (RR 0.88, 95% CI 0.82 to 0.92; 2 studies; 115 085 women), while caesarean section was reduced by 9% (OR 0.91, 95% CI 0.85 to 0.98; 6 studies; 30 192 women). We observed an 8% reduction in the risk of neonatal intensive care unit admission (RR 0.92, 95% CI 0.87 to 0.97; 2 studies; 54 569 women) in babies born to vaccinated versus not vaccinated women. In general, vaccination during pregnancy was not associated with increased risk of adverse pregnancy or perinatal outcomes. Pain at the injection site was the most common side effect reported (77%, 95% CI 52% to 94%; 11 studies; 27 195 women). Conclusion: COVID-19 vaccines are effective in preventing SARS-CoV-2 infection and related complications in pregnant women. PROSPERO registration number: CRD42020178076.
- 4 April 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (4) , e014247
Top Cited PapersOpen AccessEffectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis
Objective: To assess the effects of COVID-19 vaccines in women before or during pregnancy on SARS-CoV-2 infection-related, pregnancy, offspring and reactogenicity outcomes. Design: Systematic review and meta-analysis. Data sources: Major databases between December 2019 and January 2023. Study selection: Nine pairs of reviewers contributed to study selection. We included test-negative designs, comparative cohorts and randomised trials on effects of COVID-19 vaccines on infection-related and pregnancy outcomes. Non-comparative cohort studies reporting reactogenicity outcomes were also included. Quality assessment, data extraction and analysis: Two reviewers independently assessed study quality and extracted data. We undertook random-effects meta-analysis and reported findings as HRs, risk ratios (RRs), ORs or rates with 95% CIs. Results: Sixty-seven studies (1 813 947 women) were included. Overall, in test-negative design studies, pregnant women fully vaccinated with any COVID-19 vaccine had 61% reduced odds of SARS-CoV-2 infection during pregnancy (OR 0.39, 95% CI 0.21 to 0.75; 4 studies, 23 927 women; I2=87.2%) and 94% reduced odds of hospital admission (OR 0.06, 95% CI 0.01 to 0.71; 2 studies, 868 women; I2=92%). In adjusted cohort studies, the risk of hypertensive disorders in pregnancy was reduced by 12% (RR 0.88, 95% CI 0.82 to 0.92; 2 studies; 115 085 women), while caesarean section was reduced by 9% (OR 0.91, 95% CI 0.85 to 0.98; 6 studies; 30 192 women). We observed an 8% reduction in the risk of neonatal intensive care unit admission (RR 0.92, 95% CI 0.87 to 0.97; 2 studies; 54 569 women) in babies born to vaccinated versus not vaccinated women. In general, vaccination during pregnancy was not associated with increased risk of adverse pregnancy or perinatal outcomes. Pain at the injection site was the most common side effect reported (77%, 95% CI 52% to 94%; 11 studies; 27 195 women). Conclusion: COVID-19 vaccines are effective in preventing SARS-CoV-2 infection and related complications in pregnant women. PROSPERO registration number: CRD42020178076.
- Open Access
- 6 December 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 67, 102264
Vulnerabilities and reparative strategies during pregnancy, childbirth, and the postpartum period: moving from rhetoric to action
- 6 December 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 67, 102264
Open AccessVulnerabilities and reparative strategies during pregnancy, childbirth, and the postpartum period: moving from rhetoric to action
- Open Access
- 30 August 2023
- Published by Bioscientifica in Endocrine Connections
- Vol. 12 (11)
Improving emotional and psychosexual well-being screening in women living with polycystic ovary syndrome: experiences from the United Kingdom and India
With increasing evidence of emotional well-being disorders associated with polycystic ovary syndrome (PCOS), effective screening processes are of utmost importance. We studied the impact of using questionnaires to screen for emotional and psychosexual well-being across different models of care for PCOS. We analysed the data from the surveys to assess the difference in the prevalence of emotional and psychosexual ill-being across ethnicity and region. In this prospective cohort study, we invited all women attending consultations for PCOS in Birmingham, UK, and Bengaluru and Navi Mumbai, India. Those who consented to participate in the study were invited to complete a pre-clinic survey about socio-demographic data, Hospital Anxiety and Depression Scale (HADS), Body Image Concern Inventory (BICI), Beliefs about Obese Person scale (BAOP), and Female Sexual Function Index score (FSFI) and a post-clinic survey on clinic experience, lifestyle advice, and specialist referral. A total of 115 women were included in this study. The rate of questionnaire completion was 98.3% (113/115), 97.4% (112/115), 93.04% (107/115), and 84.3% (97/115) for HADS, BICI, BAOP, and FSFI, respectively. In the post-clinic survey, 28.8% reported they were screened for anxiety, 27.1% for depression, and 45.8% for body image concerns. The prevalence of anxiety, depression, and body dysmorphic disorder through pre-clinic survey was 56.5% (50.0% UK vs 59.5% India, P = 0.483), 16.5% (13.9% UK vs 17.7% India, P = 0.529), and 29.6% (36.1% UK vs 26.6% India, P = 0.208), respectively. Surveys with validated questionnaires can improve screening for emotional and psychosexual well-being associated with PCOS which may be missed by ad hoc screening during consultations.
- 30 August 2023
- Published by Bioscientifica in Endocrine Connections
- Vol. 12 (11)
Open AccessImproving emotional and psychosexual well-being screening in women living with polycystic ovary syndrome: experiences from the United Kingdom and India
With increasing evidence of emotional well-being disorders associated with polycystic ovary syndrome (PCOS), effective screening processes are of utmost importance. We studied the impact of using questionnaires to screen for emotional and psychosexual well-being across different models of care for PCOS. We analysed the data from the surveys to assess the difference in the prevalence of emotional and psychosexual ill-being across ethnicity and region. In this prospective cohort study, we invited all women attending consultations for PCOS in Birmingham, UK, and Bengaluru and Navi Mumbai, India. Those who consented to participate in the study were invited to complete a pre-clinic survey about socio-demographic data, Hospital Anxiety and Depression Scale (HADS), Body Image Concern Inventory (BICI), Beliefs about Obese Person scale (BAOP), and Female Sexual Function Index score (FSFI) and a post-clinic survey on clinic experience, lifestyle advice, and specialist referral. A total of 115 women were included in this study. The rate of questionnaire completion was 98.3% (113/115), 97.4% (112/115), 93.04% (107/115), and 84.3% (97/115) for HADS, BICI, BAOP, and FSFI, respectively. In the post-clinic survey, 28.8% reported they were screened for anxiety, 27.1% for depression, and 45.8% for body image concerns. The prevalence of anxiety, depression, and body dysmorphic disorder through pre-clinic survey was 56.5% (50.0% UK vs 59.5% India, P = 0.483), 16.5% (13.9% UK vs 17.7% India, P = 0.529), and 29.6% (36.1% UK vs 26.6% India, P = 0.208), respectively. Surveys with validated questionnaires can improve screening for emotional and psychosexual well-being associated with PCOS which may be missed by ad hoc screening during consultations.
- Open Access
- 8 March 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (8) , 978-986
Emotional and psychosexual well‐being is influenced by ethnicity and birthplace in women and individuals with polycystic ovary syndrome in the UK and India
Objective: To assess the association of ethnicity and birthplace on emotional and psychosexual well‐being in women with polycystic ovary syndrome (PCOS).Design: Cross‐sectional study.Setting: Community recruitment via social media campaigns.Population: Women with PCOS completing an online questionnaire in September–October 2020 (UK) and May–June 2021 (India).Methods: The survey has five components, with a baseline information and sociodemographic section followed by four validated questionnaires: Hospital Anxiety and Depression Scale (HADS); Body Image Concern Inventory (BICI); Beliefs About Obese Persons Scale (BAOP); and Female Sexual Function Index (FSFI).Main outcome measures: We used adjusted linear and logistic regression models, adjusting for age, education, marital status and parity, to evaluate the impact of ethnicity and birthplace on questionnaire scores and outcomes (anxiety and/or depression, HADS ≥ 11; body dysmorphic disorder (BDD), BICI ≥ 72).Results: A total of 1008 women with PCOS were included. Women of non‐white ethnicity (613/1008) reported higher rates of depression (OR 1.96, 95% CI 1.41–2.73) and lower BDD (OR 0.57, 95% CI 0.41–0.79) than white women (395/1008). Women born in India (453/1008) had higher anxiety (OR 1.57, 95% CI 1.00–2.46) and depression (OR 2.20, 95% CI 1.52–3.18) but lower BDD rates (OR 0.42, 95% CI 0.29–0.61) than women born in the UK (437/1008). All sexual domains, excluding desire, scored lower for non‐white women and women born in India.Conclusions: Non‐white women and women born in India reported higher emotional and sexual dysfunction, whereas white women and women born in the UK reported higher body image concerns and weight stigma. Ethnicity and birthplace need to be considered for tailored, multidisciplinary care.
- 8 March 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 130 (8) , 978-986
Open AccessEmotional and psychosexual well‐being is influenced by ethnicity and birthplace in women and individuals with polycystic ovary syndrome in the UK and India
Objective: To assess the association of ethnicity and birthplace on emotional and psychosexual well‐being in women with polycystic ovary syndrome (PCOS).Design: Cross‐sectional study.Setting: Community recruitment via social media campaigns.Population: Women with PCOS completing an online questionnaire in September–October 2020 (UK) and May–June 2021 (India).Methods: The survey has five components, with a baseline information and sociodemographic section followed by four validated questionnaires: Hospital Anxiety and Depression Scale (HADS); Body Image Concern Inventory (BICI); Beliefs About Obese Persons Scale (BAOP); and Female Sexual Function Index (FSFI).Main outcome measures: We used adjusted linear and logistic regression models, adjusting for age, education, marital status and parity, to evaluate the impact of ethnicity and birthplace on questionnaire scores and outcomes (anxiety and/or depression, HADS ≥ 11; body dysmorphic disorder (BDD), BICI ≥ 72).Results: A total of 1008 women with PCOS were included. Women of non‐white ethnicity (613/1008) reported higher rates of depression (OR 1.96, 95% CI 1.41–2.73) and lower BDD (OR 0.57, 95% CI 0.41–0.79) than white women (395/1008). Women born in India (453/1008) had higher anxiety (OR 1.57, 95% CI 1.00–2.46) and depression (OR 2.20, 95% CI 1.52–3.18) but lower BDD rates (OR 0.42, 95% CI 0.29–0.61) than women born in the UK (437/1008). All sexual domains, excluding desire, scored lower for non‐white women and women born in India.Conclusions: Non‐white women and women born in India reported higher emotional and sexual dysfunction, whereas white women and women born in the UK reported higher body image concerns and weight stigma. Ethnicity and birthplace need to be considered for tailored, multidisciplinary care.
- Open Access
- 11 November 2022
- Published by BMJ in BMJ Global Health
- Vol. 7 (11) , e010060
Global variations in the burden of SARS-CoV-2 infection and its outcomes in pregnant women by geographical region and country’s income status: a meta-analysis
Introduction The prevalence of COVID-19 and its impact varied between countries and regions. Pregnant women are at high risk of COVID-19 complications compared with non-pregnant women. The magnitude of variations, if any, in SARS-CoV-2 infection rates and its health outcomes among pregnant women by geographical regions and country’s income level is not known. Methods We performed a random-effects meta-analysis as part of the ongoing PregCOV-19 living systematic review (December 2019 to April 2021). We included cohort studies on pregnant women with COVID-19 reporting maternal (mortality, intensive care admission and preterm birth) and offspring (mortality, stillbirth, neonatal intensive care admission) outcomes and grouped them by World Bank geographical region and income level. We reported results as proportions with 95% confidence intervals (CI). Results We included 311 studies (2 003 724 pregnant women, 57 countries). The rates of SARS-CoV-2 infection in pregnant women varied significantly by region (pConclusion The rates of SARS-CoV-2 infection in pregnant women vary globally, and its health outcomes mirror the COVID-19 burden and global maternal and offspring inequalities. PROSPERO registration number CRD42020178076.
- 11 November 2022
- Published by BMJ in BMJ Global Health
- Vol. 7 (11) , e010060
Open AccessGlobal variations in the burden of SARS-CoV-2 infection and its outcomes in pregnant women by geographical region and country’s income status: a meta-analysis
Introduction The prevalence of COVID-19 and its impact varied between countries and regions. Pregnant women are at high risk of COVID-19 complications compared with non-pregnant women. The magnitude of variations, if any, in SARS-CoV-2 infection rates and its health outcomes among pregnant women by geographical regions and country’s income level is not known. Methods We performed a random-effects meta-analysis as part of the ongoing PregCOV-19 living systematic review (December 2019 to April 2021). We included cohort studies on pregnant women with COVID-19 reporting maternal (mortality, intensive care admission and preterm birth) and offspring (mortality, stillbirth, neonatal intensive care admission) outcomes and grouped them by World Bank geographical region and income level. We reported results as proportions with 95% confidence intervals (CI). Results We included 311 studies (2 003 724 pregnant women, 57 countries). The rates of SARS-CoV-2 infection in pregnant women varied significantly by region (pConclusion The rates of SARS-CoV-2 infection in pregnant women vary globally, and its health outcomes mirror the COVID-19 burden and global maternal and offspring inequalities. PROSPERO registration number CRD42020178076.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Simulation via Instant Messaging - Birmingham Advance helps to narrow the gap of knowledge and expectations between clinicians and women with polycystic ovary syndrome: A SIMBA-PCOS mixed-method study
Introduction: Educational interventions for healthcare professionals (HCPs) in diabetes and endocrinology often limits patient and public involvement (PPI). We studied the effectiveness of Simulation via Instant Messaging-Birmingham Advance (SIMBA) as a tool to improve knowledge about polycystic ovary syndrome (PCOS) in HCP and women with PCOS. Additionally, we aimed to identify and reduce gaps in knowledge and expectations between HCP and women living with PCOS. Methods: HCP and women with PCOS underwent simulation-based and workshop-based learning respectively on four PCOS case scenarios. These were followed by a debriefing session chaired by experts in PCOS, where women with PCOS also shared their experiences of PCOS. Data on confidence and expectations regarding PCOS were collected pre-and post-SIMBA. Wilcoxon Signed-Rank test was used to compare changes in confidence pre-and post-simulation. Thematic induction was used to identify areas of gaps between expectation and care from questionnaires and discussion session involving HCP and women with PCOS. Results: 25 HCP and 15 women with PCOS completed our questionnaires. HCPs reported increased confidence to manage PCOS cases (simulated:+41.0%, PPP=0.0141) and 17.7% (P=0.0002) increase in PPI participants’ confidence in HCPs to diagnose and manage PCOS-related issues respectively. Thematic analysis revealed four areas of gaps between expectation and care—delays in diagnosis, lack of information provided regarding further symptoms development and long-term complications, symptom-focused care instead of a holistic approach, and lack of information provided for the treatment they receive. Conclusion: SIMBA-PCOS is an effective tool for both women with PCOS and HCPs to enhance their confidence and understand each other’s perspectives. It also helped reduce gaps in knowledge and expectations between women with PCOS and HCPs.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Simulation via Instant Messaging - Birmingham Advance helps to narrow the gap of knowledge and expectations between clinicians and women with polycystic ovary syndrome: A SIMBA-PCOS mixed-method study
Introduction: Educational interventions for healthcare professionals (HCPs) in diabetes and endocrinology often limits patient and public involvement (PPI). We studied the effectiveness of Simulation via Instant Messaging-Birmingham Advance (SIMBA) as a tool to improve knowledge about polycystic ovary syndrome (PCOS) in HCP and women with PCOS. Additionally, we aimed to identify and reduce gaps in knowledge and expectations between HCP and women living with PCOS. Methods: HCP and women with PCOS underwent simulation-based and workshop-based learning respectively on four PCOS case scenarios. These were followed by a debriefing session chaired by experts in PCOS, where women with PCOS also shared their experiences of PCOS. Data on confidence and expectations regarding PCOS were collected pre-and post-SIMBA. Wilcoxon Signed-Rank test was used to compare changes in confidence pre-and post-simulation. Thematic induction was used to identify areas of gaps between expectation and care from questionnaires and discussion session involving HCP and women with PCOS. Results: 25 HCP and 15 women with PCOS completed our questionnaires. HCPs reported increased confidence to manage PCOS cases (simulated:+41.0%, PPP=0.0141) and 17.7% (P=0.0002) increase in PPI participants’ confidence in HCPs to diagnose and manage PCOS-related issues respectively. Thematic analysis revealed four areas of gaps between expectation and care—delays in diagnosis, lack of information provided regarding further symptoms development and long-term complications, symptom-focused care instead of a holistic approach, and lack of information provided for the treatment they receive. Conclusion: SIMBA-PCOS is an effective tool for both women with PCOS and HCPs to enhance their confidence and understand each other’s perspectives. It also helped reduce gaps in knowledge and expectations between women with PCOS and HCPs.
- Open Access
- 12 August 2022
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 31 (6) , e13682
Identifying strategies to support gynaecological cancer patients and carers during COVID‐19: Learning from patient–charity interactions
Objectives Supporting cancer patients during COVID-19 has posed unique challenges for health care providers. We investigated patient and carer-charity interactions to explore the role of charities and identify concerns expressed by patients. The study aims to address these concerns and learn how health care providers can support patients. Methods Digital interactions on forum posts and social media were collected from four gynaecological cancer charities from March-May 2019 (before COVID-19) and 2020 (during COVID-19). Thematic analysis of forum posts and semistructured charity staff interviews investigated patient and charity-focused perspectives. Results Thematic analysis of forum posts and charity staff interviews (n = 8) revealed three consistent themes: (1) Health care changes and the effect on cancer management concerns; (2) psychological impact of lockdown isolation and anxiety of changed treatment; (3) the complexity of shielding guidance on self-risk assessment. Patients valued cancer charities' responses through digital and conventional methods (webinars, social media, forums, and websites). Conclusion Gynaecological cancer patients had concerns about the risk and impact of changed treatment plans, contacting charities as the first port of call when anxious not to burden health systems. Real-time analysis of charities' communications can be used to identify concerns and to proactively provide patient support, together with health care providers.
- 12 August 2022
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 31 (6) , e13682
Open AccessIdentifying strategies to support gynaecological cancer patients and carers during COVID‐19: Learning from patient–charity interactions
Objectives Supporting cancer patients during COVID-19 has posed unique challenges for health care providers. We investigated patient and carer-charity interactions to explore the role of charities and identify concerns expressed by patients. The study aims to address these concerns and learn how health care providers can support patients. Methods Digital interactions on forum posts and social media were collected from four gynaecological cancer charities from March-May 2019 (before COVID-19) and 2020 (during COVID-19). Thematic analysis of forum posts and semistructured charity staff interviews investigated patient and charity-focused perspectives. Results Thematic analysis of forum posts and charity staff interviews (n = 8) revealed three consistent themes: (1) Health care changes and the effect on cancer management concerns; (2) psychological impact of lockdown isolation and anxiety of changed treatment; (3) the complexity of shielding guidance on self-risk assessment. Patients valued cancer charities' responses through digital and conventional methods (webinars, social media, forums, and websites). Conclusion Gynaecological cancer patients had concerns about the risk and impact of changed treatment plans, contacting charities as the first port of call when anxious not to burden health systems. Real-time analysis of charities' communications can be used to identify concerns and to proactively provide patient support, together with health care providers.